Medline (NASDAQ:MDLN) Earns Buy Rating from Analysts at Bank of America

Bank of America assumed coverage on shares of Medline (NASDAQ:MDLN) in a report released on Monday, Marketbeat reports. The firm issued a buy rating and a $50.00 price target on the stock.

Several other research firms also recently commented on MDLN. Rothschild & Co Redburn initiated coverage on Medline in a research note on Monday. They issued a “neutral” rating and a $42.00 price objective for the company. Redburn Partners set a $42.00 target price on shares of Medline in a report on Monday. Barclays assumed coverage on shares of Medline in a research note on Monday. They issued an “overweight” rating and a $50.00 price target on the stock. Royal Bank Of Canada assumed coverage on shares of Medline in a research note on Monday. They set an “outperform” rating and a $47.00 price objective for the company. Finally, Robert W. Baird began coverage on shares of Medline in a research note on Monday. They issued an “outperform” rating and a $48.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Medline currently has a consensus rating of “Moderate Buy” and an average price target of $46.70.

Medline Stock Performance

NASDAQ MDLN opened at $43.41 on Monday. Medline has a 1-year low of $34.89 and a 1-year high of $45.50.

Insiders Place Their Bets

In other news, Director Charles N. Mills purchased 2,579,310 shares of Medline stock in a transaction dated Thursday, December 18th. The shares were purchased at an average price of $29.00 per share, with a total value of $74,799,990.00. Following the transaction, the director owned 2,441,379 shares in the company, valued at $70,799,991. This represents a -1,870.00% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Andrew J. Mills acquired 2,586,206 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The stock was acquired at an average price of $29.00 per share, for a total transaction of $74,999,974.00. Following the completion of the acquisition, the director directly owned 2,586,206 shares of the company’s stock, valued at $74,999,974. The trade was a ∞ increase in their position. The disclosure for this purchase is available in the SEC filing.

Key Headlines Impacting Medline

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Several major brokers initiated bullish coverage or set high price targets (Truist $52, Evercore $50, BTIG $50, Goldman $49, Sanford Bernstein $49, UBS $48, RBC $47, BMO $45, Leerink/Baird strong-buy). Those reports signal upward earnings/market-share expectations and provide concrete upside targets for investors, supporting the rally. Analyst Coverage & Targets (Benzinga)
• Neutral Sentiment: Widespread coverage initiations across big banks (Deutsche Bank, Jefferies, Wells Fargo, JPMorgan, Citigroup, Barclays, Mizuho, TD Cowen, Wolfe Research, Rothschild/Redburn, BNP Paribas Exane) increase the stock’s visibility and institutional research footprint—likely to lift liquidity and investor interest over time but not an immediate fundamental change on its own. Coverage Initiations (AmericanBankingNews)
• Neutral Sentiment: Press coverage highlighting a strong market debut and “aging dividend” thematic interest has helped momentum traders and retail investors take notice; this amplifies the technical lift but is not new company-specific fundamental news. Market Debut Coverage (NAI500)
• Negative Sentiment: Not all firms are uniformly bullish—BNP Paribas and Rothschild/Redb issued “hold” ratings for now. These more cautious views could cap near-term upside if other analysts temper forecasts or if results miss elevated expectations. Hold Ratings (Zacks)

Medline Company Profile

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.